On May 14, 2025, MetaVia Inc. (MTVA) announced financial results for the first quarter and provided a business update. The company recently announced positive topline results from the Phase 1 MAD trial of DA-1726 in obesity that showed statistically significant weight loss and potential best-in-class results for glucose control, waist reduction, and tolerability. MetaVia will be adding additional cohorts to the study to determine a maximum tolerated dose. The company also recently presented positive 16-week results for DA-1241 in patients with presumed MASH that showed the drug significantly reduced markers of liver injury, inflammation, and fibrosis. An end-of-Phase 2 meeting with the FDA is planned for the first half of 2025.
